Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record.

YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity

Giménez‐Bonafé, Pepita, Fedoruk, Matthew N., Whitmore, Tanis G., Akbari, Majid, Ralph, Jody L., Ettinger, Susan, Gleave, Martin E., Nelson, Colleen C.·2004·The Prostate

Abstract

BACKGROUND: Currently, the main obstacle to curing advanced prostate cancer is development of androgen independence (AI), where malignant cells acquire the ability to survive in the absence of androgens. Our initial experimental approach used cDNA microarrays to characterize changes in gene expression in the LNCaP human prostate tumor model during progression to AI. The transcription factor Y‐box binding protein (YB‐1) was shown to be one of the genes upregulated. We focused on increased YB‐1 expression during progression in clinical specimens, and further examined one of its downstream targets, P‐glycoprotein (P‐gp). METHODS: Northern blot analysis was performed on LNCaP tumor series, as well as immunohistochemical analyses of human prostate cancer tissue samples. YB‐1 was transiently transfected and transport analysis were performed to analyze P‐gp efflux activity. RESULTS: YB‐1 expression is markedly increased during benign to malignant transformation and further following androgen ablation. In addition, increased YB‐1 expression after castration in the LNCaP model is linked to upregulation of P‐gp. We demonstrate that YB‐1 upregulates P‐gp activity resulting in a 40% intracellular decrease in the P‐gp substrate vinblastine. We have also found that P‐gp increases the efflux of the endogenous androgen, dihydrotestosterone (DHT), from prostate cells and leads to decreased androgen regulated gene expression. CONCLUSIONS: We hypothesize that early in prostate cancer progression, increased expression of YB‐1 may increase P‐gp activity which may in turn lower androgen levels in the prostate tumor cells. Suppression of androgen levels may activate cell survival pathways and lead to an adaptive survival advantage of androgen independent prostate cancer cells following androgen ablation therapy. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.20023

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 165

Metadata

Authors
Giménez‐Bonafé, P., Fedoruk, M. N., Whitmore, T. G., Akbari, M., Ralph, J. L., Ettinger, S., Gleave, M. E., & Nelson, C. C.
Venue
The Prostate
Publisher
Wiley
Published
2004-01-05
Volume
59
Issue
3
Pages
337-349
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2007951687
Cited by
165
References
0
FWCI
5.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity. https://app.cochat.ai/papers/10.1002/pros.20023
The paper
Giménez‐Bonafé, P., Fedoruk, M. N., Whitmore, T. G., Akbari, M., Ralph, J. L., Ettinger, S., Gleave, M. E., & Nelson, C. C. (2004). YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity. The Prostate. https://doi.org/10.1002/pros.20023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.